Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes

Pediatric Diabetes

Volumn 17, Issue 8, 2016, Pages 642-649

  Biester, Torben ^a   Danne, Thomas ^a   Bläsig, Sarah ^a   Remus, Kerstin ^a   Aschemeier, Bärbel ^a   Kordonouri, Olga ^a   Bardtrum, Lars ^b   Haahr, Hanne ^b  

^a Diabetes Centre for Children and Adolescents   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

adolescents; children; insulin degludec insulin aspart; pharmacodynamics; pharmacokinetics

Indexed keywords

GLUCOSE; INSULIN ASPART PLUS INSULIN DEGLUDEC; ANTIDIABETIC AGENT; DRUG COMBINATION; INSULIN DEGLUDEC, INSULIN ASPART DRUG COMBINATION; LONG ACTING INSULIN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEMATOMA; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RHINOPHARYNGITIS; STANDARDIZATION; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; DRUG COMBINATION; MEAL; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; DIABETES MELLITUS, TYPE 1; DRUG COMBINATIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MEALS; MIDDLE AGED; YOUNG ADULT;

EID: 84955327109     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12358     Document Type: Article

References (30)

1. Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014: 37: 2034–2054.
2. Daneman D. State of the world's children with diabetes. Pediatr Diabetes 2009: 10: 120–126.
3. Burdick J, Chase HP, Slover RH et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics 2004: 113: e221–224.
4. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010: 33: 240–245.
5. Rewers MJ, Pillay K, de Beaufort C et al. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2014: S20: 102–114.
6. National Institute for Health and Care Excellence. Diabetes (type 1 and type 2) in children and young people: diagnosis and management. 2015 (available from https://www.nice.org.uk/guidance/ng18, accessed 09 November 2015).
7. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. 2015 (available from https://www.nice.org.uk/guidance/ng17, accessed 09 November 2015).
8. Wolfsdorf JI, Allgrove J, Craig ME et al. ISPAD Clinical Practice Consensus Guidelines 2014. Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatr Diabetes 2014: 15: 154–179.
9. Davis SN, Dunn JP. Hypoglycemia – the major barrier to good glycemic control. US Endocrine Rev 2006: 1: 2–9.
10. Barnard K, Thomas S, Royle P, Noyes K, Waugh N. Fear of hypoglycaemia in parents of young children with type 1 diabetes: a systematic review. BMC Pediatr 2010: 10: 50.
11. Havelund S, Ribel U, Hubálek F, Hoeg-Jensen T, Wahlund PO, Jonassen I. Investigation of the physico-chemical properties that enable co-formulation of basal insulin degludec with fast-acting insulin aspart. Pharm Res 2015: 32: 2250–2258.
12. Heise T, Nosek L, Roepstorff C, Chenji S, Klein O, Haahr H. Distinct prandial and basal glucose-lowering effects of insulin degludec/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes mellitus. Diabetes Ther 2014: 5: 255–265.
13. EMA. Ryzodeg. Summary of Product Characteristics. 26 Aug 2015 (available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002499/WC500139011.pdf, accessed 09 November 2015).
14. Hirsch IB, Bode B, Courreges J-P et al. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care 2012: 35: 2174–2181.
15. EMA. Note for Guidance on Clinical Investigation of Medicinal Products in the Paediatric Population. CPMP/ICH/2711/99. January 2001 (available from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002926.pdf, accessed 09 November 2015).
16. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005: 28: 1245–1249.
17. Heise T, Nosek L, Klein O, Coester H, Svendsen AL, Haahr H. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus. Diabetes Obes Metab 2015: 17: 659–664.
18. Brunner M, Pieber T, Korsatko S, Kojzar H, Svendsen AL, Haahr H. The distinct prandial and basal pharmacodynamics of IDegAsp observed in younger adults are preserved in elderly subjects with type 1 diabetes. Drugs Aging 2015: 32: 583–590.
19. Biester T, Blaesig S, Remus K et al. Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatr Diabetes 2014: 15: 27–33.
20. Thalange N, Deeb L, Iotova V et al. Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes 2015: 16: 164–176.
21. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014: 53: 787–800.
22. Kelly LA, Lane CJ, Weigensberg MJ, Toledo-Corral CM, Goran MI. Pubertal changes of insulin sensitivity, acute insulin response, and beta-cell function in overweight Latino youth. J Pediatr 2011: 158: 442–446.
23. Danne T, Biester T, Fath M et al. Earlier onset and higher early exposure of faster-acting insulin aspart vs insulin aspart in adults is retained in children and adolescents with T1D. ADA 2015. Poster 976-P.
24. US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research. General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products. Guidance for Industry December 2014 (available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM425885.pdf, accessed 09 November 2015).
25. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med 2003: 349: 1157–1167.
26. Van Haeften TW. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care 1989: 12: 641–648.
27. Chen JW, Frystyk J, Lauritzen T, Christiansen JS. Impact of insulin antibodies on insulin aspart pharmacokinetics and pharmacodynamics after 12-week treatment with multiple daily injections of biphasic insulin aspart 30 in patients with type 1 diabetes. Eur J Endocrinol 2005: 153: 907–913.
28. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. Immunological responses to exogenous insulin. Endocr Rev 2007: 28: 625–652.
29. Danne T, Bangstad HJ, Deeb L et al. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes 2014: 15: 115–134.
30. Mathieu C, Hollander P, Miranda-Palma B et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013: 98: 1154–1162.